Bertha Madras

Last updated

Bertha Kalifon Madras is a professor of psychobiology in the Department of Psychiatry and the chair of the Division of Neurochemistry at Harvard Medical School, Harvard University. She served as associate director for public education in the division on Addictions at Harvard Medical School. Madras has published research in the areas of drug addiction (particularly the effects of cocaine), ADHD, and Parkinson's disease.

Contents

Madras earned a BSc in biochemistry with honours from McGill University in 1963. [1] [2] As a J.B. Collop Fellow of the Faculty of Medicine, she was awarded a PhD in biochemistry (metabolism and pharmacology, including hallucinogens) from McGill University in 1967. [1] [2] She completed postdoctoral fellowships in biochemistry at Tufts University/Cornell University Medical College (1966–1967) as well as at the Massachusetts Institute of Technology (1967–1969). [1] [2] Thereafter, she was appointed a research associate at the Massachusetts Institute of Technology (1972–1974) as well as an assistant professor in the Departments of Pharmacology and Psychiatry at the University of Toronto. [1] [2] Dr Madras joined the Harvard Medical School as an assistant professor in 1986 and was subsequently promoted to associate professor and (full) professor – with a cross-appointment to the Department of Psychiatry at the Massachusetts General Hospital. [1] Dr. Madras also founded and chaired the Division of Neurochemistry at Harvard Medical School's New England Primate Research Centre – a multidisciplinary, translational research program which spans chemical design, molecular and cellular biology, behavioural biology, and brain imaging approaches. [1] She directs the Laboratory of Addiction Neurobiology, McLean Hospital, in conjunction with the Harvard Brain Science initiative. [3]

She is married to Peter Madras and has two daughters, two sons-in-law, and five grandchildren.[ citation needed ].

Public policy work

Madras served as the deputy director for demand reduction for the White House Office of National Drug Control Policy; [4] She was nominated by President George W. Bush in July, 2005, and unanimously confirmed by the United States Senate in 2006. [5] [6] [7] In the federal budget for Medicaid reimbursement, assurances that the majority of federal employees' healthcare insurers would reimburse for these procedures, that certain State Medicaid plans would reimburse for SBI services, that the Veterans' Administration would mandate SBI for alcohol throughout the VA system, [8] and that the Federal Health Resource Services Administration (HRSA) would implement these services in underserved populations. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]

Research

Madras has authored over 130 scientific manuscripts and book chapters, and she recently co-edited a book on the Cell Biology of Addiction. [19] Along with her collaborators, she is the recipient of 19 patents. [20]

Honours

Her co-discovery of altropane was recognized by the Association of University Technology Managers in 2006. [21]

Related Research Articles

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite it causing problems. Some definitions require evidence of dependence and withdrawal. Problematic use of alcohol has been mentioned in the earliest historical records. The World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are sometimes considered stigmatizing and to discourage seeking treatment, so diagnostic terms such as alcohol use disorder or alcohol dependence are often used instead in a clinical context.

Commonly-cited arguments for and against the prohibition of drugs include the following:

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">George Koob</span> American academic

George F. Koob is a Professor and former Chair of the Committee on the Neurobiology of Addictive Disorders at the Scripps Research Institute and Adjunct Professor of Psychology, Psychiatry, and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego. In 2014 he became the director of the National Institute on Alcohol Abuse and Alcoholism.

<span class="mw-page-title-main">Nora Volkow</span> American physician

Nora D. Volkow is a Mexican-American psychiatrist. She is currently the director of the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH).

David C. Lewis was Professor Emeritus of Medicine and Community Health and the Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies at Brown University.

Bankole A. Johnson, DSc, MD, MPhil, FRCPsych is a Nigerian psychiatrist. He served as Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia and is known for his research into addiction.

Herbert David Kleber was an American psychiatrist and substance abuse researcher. His career, centered on the evidence-based treatment of addiction, focused on scientific approaches in place of punishment and moralisms. His career focused on pathology of addiction to help patients reduce the severe discomforts of withdrawal, avoid relapse and stay in recovery.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder. The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD". Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine, cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Cannabis use disorder</span> Continued use of cannabis despite clinically significant impairment

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.

<span class="mw-page-title-main">Mark S. Gold</span>

Mark S. Gold is an American physician, professor, author, and researcher on the effects of opioids, cocaine, tobacco, and other drugs as well as food on the brain and behavior. He is married to Janice Finn Gold.

<span class="mw-page-title-main">Michael Botticelli</span> American public health official

Michael P. Botticelli is an American public health official who served as the director of the White House Office of National Drug Control Policy (ONDCP) from March 2014 until the end of President Obama's term. He was named acting director after the resignation of Gil Kerlikowske, and received confirmation from the United States Senate in February 2015. Prior to joining ONDCP, he worked in the Massachusetts Department of Public Health. Following completion of his service as ONDCP Director, he became the executive director of the Grayken Center for Addiction Medicine at the Boston Medical Center.

<span class="mw-page-title-main">Charles P. O'Brien</span> American research scientist, medical educator (born 1939)

Charles P. O'Brien is a research scientist, medical educator and a leading expert in the science and treatment of addiction. He is board certified in neurology, psychiatry and addiction psychiatry. He is currently the Kenneth E. Appel Professor of Psychiatry, and vice chair of psychiatry, in the Perelman School of Medicine at the University of Pennsylvania.

John R. Knight is an Associate Professor of Pediatrics at Harvard Medical School (HMS) and the Associate Director for Medical Education at the HMS Division on Addictions. In 1999, he founded the Center for Adolescent Substance Abuse Research (CeASAR) and its companion outpatient clinic, the Adolescent Substance Abuse Program (ASAP). CeASAR and ASAP were the first programs of their kind to be located at a children’s hospital. He is best known as the clinical scientist who developed and validated the CRAFFT substance abuse screen for adolescents. In 2008 he was named the inaugural incumbent of the Boston Children’s Hospital Endowed Chair in Developmental Medicine

<span class="mw-page-title-main">Elinore McCance-Katz</span> American physician, academic, and government official

Elinore F. McCance-Katz is an American physician, academic, and government official who served as Assistant Secretary of Health and Human Services for Mental Health and Substance Use from 2017 to 2021. Prior to assuming her current role, she was the chief medical officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities, and Hospitals and a professor at the Alpert Medical School at Brown University. Her nomination was supported by the American Psychiatric Association, which released a statement saying "Dr. McCance-Katz has a wealth of experience in academic and public sector settings in addressing mental health and substance use disorders."

<span class="mw-page-title-main">Keith Humphreys</span> American psychologist (born 1966)

Keith Humphreys is an American psychologist currently the Esther Ting Memorial Professor at Stanford University, a Senior Research Career Scientist in the Veterans Health Administration, and an Honorary Professor at the Institute of Psychiatry, King's College, London.

Narcology, from Russian нарко- + -логия is a subspecialty of psychiatry dealing with the prevention, treatment, diagnosis, social care and recovery of drug-dependent persons. The study and science of phenomena of "narcomania", "toxicomania", chronic alcoholism, and its ætiology, pathogenesis, and clinical aspects. The term for a practitioner of narcology is narcologist. In the United States, the comparable terms are "addiction medicine" and "addictionist".

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

John F. Kelly is an American-based researcher and professor of addiction medicine at Harvard Medical School. He is the Founder and Director of the Massachusetts General Hospital Recovery Research Institute, Associate Director of the MGH Center for Addiction Medicine, and Program Director of the MGH Addiction Recovery Management Service.

Amy Janes is an American psychiatry researcher. She is chief of the Cognitive and Pharmacological Neuroimaging Unit at the National Institute on Drug Abuse's Intramural Research Program. She is known for her work using multimodal neuroimaging to examine individual differences and potential therapeutics in addictive and substance use disorders. Prior to joining NIDA, Janes was an associate professor at Harvard Medical School, working at McLean Hospital, where she founded the Functional Integration of Addiction Research Laboratory.

References

  1. 1 2 3 4 5 6 "United States of America v. Schweder, et al. (2014). "Declaration of Bertha Madras, Ph.D". Case No. 2:11-CR-00449-KJM-16, in the United States District Court – Eastern District of California. Page 2" (PDF). Retrieved August 8, 2017.
  2. 1 2 3 4 "Bertha K. Madras, PHD | McLean Hospital" . Retrieved August 8, 2017.
  3. ↑ "Bertha Madras". Harvard Brain Science Initiative. Retrieved August 10, 2022.
  4. ↑ "Bertha Madras, Deputy Director for Demand Reduction, White House Office of National Drug Control Policy – ONDCP". Archived from the original on August 7, 2007. Retrieved 2008-01-15.
  5. ↑ "Office of National Drug Control Policy | The White House". Whitehousedrugpolicy.gov. Retrieved October 19, 2011.
  6. ↑ "Aphsa Health Services Division" (PDF). Nasmd.org. Retrieved October 19, 2011.[ permanent dead link ]
  7. ↑ http://staging.whitehousedrugpolicy.gov/about/madras.html%5B%5D
  8. ↑ "Archived copy". Archived from the original on May 10, 2009. Retrieved May 4, 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  9. ↑ Archived December 31, 2008, at the Wayback Machine
  10. ↑ Stephanie Whyche (May 16, 2008). "Federal Workers Get Coverage for Substance Abuse Screening". Pn.psychiatryonline.org. Archived from the original on July 29, 2012. Retrieved October 19, 2011.
  11. ↑ "National strategy focuses on screening: ONDCP demand reduction chief urges early intervention. (Office of National Drug Control Policy)". Alcoholism & Drug Abuse Weekly. February 19, 2007.
  12. ↑ Tim Caron; Matt Gever; Allison Colker (July 15, 2008). "NCSL Substance Abuse Snapshot, July 15, 2008". Ncsl.org. Archived from the original on September 8, 2012. Retrieved October 19, 2011.
  13. ↑ "National Institute on Drug Abuse to Unveil NIDAMED, Physicians' Outreach Initiative, April 6, 2009 News Release – National Institutes of Health (NIH)". Nih.gov. Retrieved October 19, 2011.
  14. ↑ "Instituto De Salud Del Estado De México". Salud.edomexico.gob.mx. Retrieved October 19, 2011.
  15. ↑ "Addictologia Hungarica – What Works to Reduce Drug Use". Archived from the original on January 23, 2008.
  16. ↑ Madras, BK; Compton, WM; Avula, D; Stegbauer, T; Stein, JB; Clark, HW (January 2009). "Drug and Alcohol Dependence : Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later". Drug Alcohol Depend. 99 (1–3): 280–95. doi:10.1016/j.drugalcdep.2008.08.003. PMC   2760304 . PMID   18929451.
  17. ↑ Madras, BK; Compton, WM; Avula, D; Stegbauer, T; Stein, JB; Clark, HW (January 2009). "Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later". Drug Alcohol Depend. 99 (1–3): 280–95. doi:10.1016/j.drugalcdep.2008.08.003. PMC   2760304 . PMID   18929451.
  18. ↑ Bertha K. Madras: Office of National Drug Control Policy: A scientist in drug policy in Annals of the New York Academy of Sciences, 1187: Addiction Reviews 2; pages 370–402, 2010.
  19. ↑ Madras BK. Introduction to "Cell Biology of Addiction". Editors: Madras BK, Colvis CM, Pollack JD, Rutter JL, Shurtleff D, von Zastrow M, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 1–12, 2006.
  20. ↑ "United States Patent and Trademark Office". Uspto.gov. December 1, 1994. Retrieved October 19, 2011.
  21. ↑ Association of University Technology Managers 2006 Better World Reports: "Technology Transfer Stories: 25 Innovations That Changed the World" [ dead link ]

PubMed search for articles by Bertha Madras

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.